Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial-Reference-Cited by-同舟云学术

Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial

Published:2015-01 Issue:1 Volume:2 Page:e12-e19
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Gross Robert,Zheng Lu,Rosa Alberto La,Sun Xin,Rosenkranz Susan L,Cardoso Sandra Wagner,Ssali Francis,Camp Rob,Godfrey Catherine,Cohn Susan E,Robbins Gregory K,Chisada Anthony,Wallis Carole L,Reynolds Nancy R,Lu Darlene,Safren Steven A,Hosey Lara,Severe Patrice,Collier Ann C

Funder

National Institute of Allergy and Infectious Diseases

AIDS Clinical Trials Group Clinical Trials Unit

Michael Ssemmanda and Haspha Nassolo (Joint Clinical Research Centre clinical research site 12401

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference28 articles.

1. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies;Johnson;PLoS Med,2013

2. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis;Mills;JAMA,2006

3. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes;Nachega;Ann Intern Med,2007